Biomarkers and correlative endpoints for immunotherapy trials

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

Volumn , Issue , 2013, Pages

  Morse, Michael A ^a   Osada, Takuya ^a   Hobeika, Amy ^a   Patel, Sandip ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADVERSE EFFECTS; BIOASSAY; BLOOD; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METHODOLOGY; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; TIME; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84946210882     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.1200/EdBook_AM.2013.33.e287     Document Type: Review

References (0)